Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylene Blue in Healthy Aging, MCI, and Alzheimer's Disease
NCT02380573Phase 2Completed
- Sponsor
- UT Health San Antonio
- Start
- Jul 2015
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of methylene blue in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI), sponsored by UT Health San Antonio. Started Jul 2015; status: completed.
02
Drugs
methylene blue
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT02380573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02380573.